HIV drugs News and Research

RSS

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV.

7 Jul 2015

Clinical trial suggests HIV patients should start therapy sooner rather than later

Findings from a large-scale clinical trial have shown that people with HIV should start antiretroviral therapy as soon as they have been diagnosed, irrespective of what their CD4+ count is...

28 May 2015

Bio-Rad grants Beckman Coulter exclusive distribution rights for access HIV and Hepatitis C assays

Bio-Rad is extending its agreement with Beckman Coulter and has named the company exclusive global distributor of Bio-Rad’s Access HIV combo assay and the Access hepatitis C virus (HCV) assay in select geographies...

From Beckman Coulter Diagnostics 21 Apr 2015

PaMZ drug regimen shows potential to improve treatment for MDR-TB

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun.

19 Mar 2015

Salk scientists move one step closer to creating drug that could prevent HIV virus

Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced disease. It sounds like science fiction, but Salk scientists have gotten one step closer to creating such a drug by customizing a powerful defense system used by many bacteria and training this scissor-like machinery to recognize the HIV virus.

10 Mar 2015

Scientists develop promising new HIV vaccine agent

In a study that involved researchers from over a dozen institutions, the anti-HIV agent protected monkeys from every strain of HIV-1, HIV-2 and SIV (simian immunodeficiency virus) for at least 34 weeks.

19 Feb 2015

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

The HIV Prevention Trials Network has launched two new phase 2 studies, HPTN 076 and HPTN 077, which are designed to evaluate new drugs to protect people from getting infected with HIV.

19 Feb 2015

UNICEF and UNAIDS go ‘All In’ to end the AIDS epidemic among adolescents

AIDS has become the second leading cause of death among adolescents globally. Just one in four children and adolescents under the age of 15 have access to life-saving antiretroviral treatment. Deaths are declining in all age groups, except among 10–19 year olds.

17 Feb 2015

Using HIV drugs to treat AMD: an interview with Dr Mark Young

NRTIs are compounds which were originally developed in the 1960s as anti-cancer agents. They are similar in structure to the bases which make up DNA, and it was hoped that they would interfere with DNA replication in fast-growing cancer cells, slowing down or stopping tumour growth.

7 Jan 2015

CCR5 receptor plays key role in driving prostate cancer metastases

Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers show that the receptor CCR5 best known for its role in HIV therapy, may also be involved in driving the spread of prostate cancer to the bone.

1 Dec 2014

HIV drugs could be harnessed to treat leading cause of blindness

An established class of drugs, traditionally used to control HIV/AIDS infections, could soon be harnessed to treat the leading cause of blindness and visual impairment in the UK, for which currently there exists no cure.

27 Nov 2014

State highlights: Texas lawmaker proposes '3 strikes' for nursing homes

New Yorker Deadra Malloy was diagnosed with HIV in 1988, but she remained healthy for so long she wasn't completely convinced she was positive.

9 Sep 2014

Report says feds stop public disclosure of serious hospital errors

USA Today reports the federal government has stopped publicly reporting when hospitals leave foreign objects in patients' bodies or make other life-threatening mistakes. Meanwhile, Medicare spent more than $30 million on questionable HIV medications in 2012 and the agency is resuming audits for some fee-for-service claims.

7 Aug 2014

HIV drugs News and Research

Southern Research receives $22 million to support HIV cure initiative

Clinical trial suggests HIV patients should start therapy sooner rather than later

Bio-Rad grants Beckman Coulter exclusive distribution rights for access HIV and Hepatitis C assays

PaMZ drug regimen shows potential to improve treatment for MDR-TB

Salk scientists move one step closer to creating drug that could prevent HIV virus

Scientists develop promising new HIV vaccine agent

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

UNICEF and UNAIDS go ‘All In’ to end the AIDS epidemic among adolescents

Using HIV drugs to treat AMD: an interview with Dr Mark Young

CCR5 receptor plays key role in driving prostate cancer metastases

HIV drugs could be harnessed to treat leading cause of blindness

State highlights: Texas lawmaker proposes '3 strikes' for nursing homes

Report says feds stop public disclosure of serious hospital errors

First Edition: August 6, 2014

Washington bioengineers discover potential method to protect women from contracting HIV

Advancements in HIV treatment help patients live longer

Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

New technique to examine how proteins interact at level of single HIV viral particle

TB Alliance advances first-ever TB drug regimen to global Phase 3 clinical trial

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News